{"id":153960,"date":"2025-10-30T20:10:17","date_gmt":"2025-10-30T20:10:17","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/153960\/"},"modified":"2025-10-30T20:10:17","modified_gmt":"2025-10-30T20:10:17","slug":"fda-issues-formal-guideline-waiving-clinical-efficacy-studies-for-biosimilars-confirming-professor-niazis-15-year-campaign-to-cut-biologic-drug-costs","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/153960\/","title":{"rendered":"FDA Issues Formal Guideline Waiving Clinical Efficacy Studies for Biosimilars, Confirming Professor Niazi’s 15-Year Campaign to Cut Biologic Drug Costs"},"content":{"rendered":"

A Landmark Regulatory Shift Validates Professor Sarfaraz K. Niazi’s Vision to Make Biologics as Affordable as Generics<\/p>\n

CHICAGO, Oct. 29, 2025 \/PRNewswire\/ — In a historic move reshaping global drug development, the U.S. Food and Drug Administration (FDA) today issued a formal guideline eliminating the requirement for clinical efficacy studies (CES) in biosimilar approvals, a change long championed by Professor Sarfaraz K. Niazi, Ph.D., Adjunct Professor at the University of Illinois.<\/p>\n

https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-moves-accelerate-biosimilar-development-and-lower-drug-costs?utm_medium=email&utm_source=govdelivery<\/a> <\/p>\n


\n
\n
\n <\/p>\n

\"Professor<\/a><\/p>\n


\n
\n
\n
\n
\n
\n Professor Sarfaraz K. Niazi Secures First-Ever FDA Acceptance to Waive Clinical Efficacy Studies for Monoclonal Antibody Biosimilars
\n <\/p>\n

https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product-updated-recommendations?utm_medium=email&utm_source=govdelivery<\/a> <\/p>\n

This official FDA action marks the culmination of a fifteen-year scientific and regulatory effort led by Professor\u00a0Niazi, who has consistently argued that CES add no meaningful value to biosimilar assessment because they cannot fail once analytical and functional similarity is proven.<\/p>\n

“Today’s FDA guideline finally validates what I have been saying for years \u2014 that clinical efficacy studies are scientifically redundant, wasteful, and unethical when similarity is already proven. This moment will change the economics of biologic drugs forever,” said Professor\u00a0Niazi.<\/p>\n

A 15-Year Journey to Transform Biologic Regulation
<\/b>Over the past decade and a half, Professor Niazi has engaged in an unprecedented campaign of over 50 peer-reviewed publications, multiple citizen petitions, and direct dialogues with FDA leadership. His mission: to demonstrate that biosimilars could be approved through rigorous analytical and functional testing alone \u2014 without costly and repetitive human efficacy trials.<\/p>\n

Although his own biosimilar products previously received CES waivers, skepticism persisted across the biopharmaceutical industry. The FDA’s formal issuance of this guideline today removes all doubt, confirming Professor Niazi’s position and ushering in an era where biosimilars can be developed at near-generic cost.<\/p>\n

Regulatory Reforms Now Incorporated in the FDA Framework
<\/b>The new FDA guidance document enshrines a series of reforms first proposed by Professor Niazi, transforming the Biologics Price Competition and Innovation Act (BPCIA) landscape:<\/p>\n\n\n

Legacy Requirement <\/p>\n<\/td>\n\n

Current FDA Position (Post-Guideline) <\/p>\n<\/td>\n<\/tr>\n\n\n

Tier-based analytical testing <\/p>\n<\/td>\n\n

Eliminated <\/p>\n<\/td>\n<\/tr>\n\n\n

Animal toxicology studies <\/p>\n<\/td>\n\n

Removed <\/p>\n<\/td>\n<\/tr>\n\n\n

Immunogenicity testing (insulins) <\/p>\n<\/td>\n\n

Waived \u2013 Precedent for all biologics <\/p>\n<\/td>\n<\/tr>\n\n\n

Interchangeability studies <\/p>\n<\/td>\n\n

Abolished <\/p>\n<\/td>\n<\/tr>\n\n\n

Non-U.S. reference products <\/p>\n<\/td>\n\n

Accepted if identical <\/p>\n<\/td>\n<\/tr>\n\n\n

Clinical efficacy for cytokines <\/p>\n<\/td>\n\n

Waived <\/p>\n<\/td>\n<\/tr>\n\n\n

Clinical efficacy for antibodies <\/p>\n<\/td>\n\n

Now Formally Waived \u2014 Announced Today <\/p>\n<\/td>\n<\/tr>\n

These reforms collectively reduce biosimilar development costs by over 90 percent, aligning them with the economics of small-molecule generics and dramatically accelerating patient access to advanced biologics.<\/p>\n

From “Biogenerics” to Global Access
<\/b>Professor Niazi’s legacy in biosimilars is foundational: he coined the term “biosimilar,” founded the first U.S. biosimilar company, and authored the first book on the subject. Initially referring to them as biogenerics, he later adopted the term biosimilars at the FDA’s request \u2014 a term now synonymous with high-quality, low-cost biologics.<\/p>\n

“The issuance of this guideline makes biosimilars truly biogeneric. I encourage all generic-drug companies to enter this field \u2014 the science is proven, the regulatory path is open, and the humanitarian need is undeniable,” said Niazi.<\/p>\n

The Road Ahead
<\/b>Professor Niazi is now focusing on additional structural reforms to remove remaining inefficiencies in the biologic regulatory ecosystem, including:<\/p>\n